MONTREAL, Feb. 7 /PRNewswire/ -- Osprey Pharmaceuticals Limited, a privately held biotechnology company focused on treating chronic diseases through a family of first-in-class therapeutic proteins, today announced that CEO Phil Coggins will present an update of the company's activities at the 9th Annual BIO CEO & Investor Conference 2007. The presentation will take place on Monday, Feb. 12 at 1:15 p.m. Eastern Time in the Park Avenue Suite Center North at The Waldorf-Astoria Hotel in New York.
About Osprey Pharmaceuticals Ltd.
Osprey Pharmaceuticals Limited is a privately held biotechnology company focused on commercializing a unique family of therapeutic proteins capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The company's patented Leukocyte Population Modulators selectively and systematically destroy these disease-related leukocytes by infiltrating the chemokine system -- a complex network of small proteins and their receptors that regulate the movement and activity of leukocytes. The company expects to initiate a Phase I/II trial for chronic kidney disease in the second half of 2007.
Osprey has developed a portfolio of 12 preclinical product candidates addressing a variety of diseases including cancer, cardiovascular disease, and neurological disorders, and the company anticipates initiating at least one clinical trial annually over the next three years. Osprey minimizes the risks inherent to drug development and commercialization by using a technology that can rapidly generate new product candidates, and then uniformly applying standardized testing and manufacturing protocols across its portfolio. Osprey Pharmaceuticals is based in Montreal, Canada and can be found online at www.ospreypharma.com.
Contacts Phil Coggins PhD Or Susan Thomas or John Cummings President & CEO Burns McClellan on Behalf of Osprey coggins@ospreypharma.comjcummings@burnsmc.comsthomas@burnsmc.com Tel: 415-352-6262 Robert Wagstaff Vice President, Finance wagstaff@ospreypharma.com Tel: 514-336-3118
Osprey Pharmaceuticals LimitedCONTACT: Phil Coggins PhD, President & CEO, coggins@ospreypharma.com,Robert Wagstaff, Vice President, Finance, wagstaff@ospreypharma.com, bothof Osprey Pharmaceuticals Limited, +1-514-336-3118; or Susan Thomas,sthomas@burnsmc.com, or John Cummings, jcummings@burnsmc.com, both of BurnsMcClellan on Behalf of Osprey, +1-415-352-6262
Web site: http://www.ospreypharma.com/
